These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 19125120)

  • 1. Vitamin D insufficiency and musculoskeletal symptoms in breast cancer survivors on aromatase inhibitor therapy.
    Waltman NL; Ott CD; Twiss JJ; Gross GJ; Lindsey AM
    Cancer Nurs; 2009; 32(2):143-50. PubMed ID: 19125120
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of baseline serum vitamin D levels on aromatase inhibitors induced musculoskeletal symptoms: results from the IBIS-II, chemoprevention study using anastrozole.
    Singh S; Cuzick J; Mesher D; Richmond B; Howell A
    Breast Cancer Res Treat; 2012 Apr; 132(2):625-9. PubMed ID: 22198469
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized, blinded trial of vitamin D3 for treating aromatase inhibitor-associated musculoskeletal symptoms (AIMSS).
    Shapiro AC; Adlis SA; Robien K; Kirstein MN; Liang S; Richter SA; Lerner RE
    Breast Cancer Res Treat; 2016 Feb; 155(3):501-12. PubMed ID: 26868123
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A study of the effects of the aromatase inhibitors anastrozole and letrozole on bone metabolism in postmenopausal women with estrogen receptor-positive breast cancer.
    McCaig FM; Renshaw L; Williams L; Young O; Murray J; Macaskill EJ; McHugh M; Hannon R; Dixon JM
    Breast Cancer Res Treat; 2010 Feb; 119(3):643-51. PubMed ID: 19941160
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of a switch of aromatase inhibitors on musculoskeletal symptoms in postmenopausal women with hormone-receptor-positive breast cancer: the ATOLL (articular tolerance of letrozole) study.
    Briot K; Tubiana-Hulin M; Bastit L; Kloos I; Roux C
    Breast Cancer Res Treat; 2010 Feb; 120(1):127-34. PubMed ID: 20035381
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of vitamin D supplementation on serum 25-hydroxy vitamin D levels, joint pain, and fatigue in women starting adjuvant letrozole treatment for breast cancer.
    Khan QJ; Reddy PS; Kimler BF; Sharma P; Baxa SE; O'Dea AP; Klemp JR; Fabian CJ
    Breast Cancer Res Treat; 2010 Jan; 119(1):111-8. PubMed ID: 19655244
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vitamin D and aromatase inhibitor-induced musculoskeletal symptoms (AIMSS): a phase II, double-blind, placebo-controlled, randomized trial.
    Rastelli AL; Taylor ME; Gao F; Armamento-Villareal R; Jamalabadi-Majidi S; Napoli N; Ellis MJ
    Breast Cancer Res Treat; 2011 Aug; 129(1):107-16. PubMed ID: 21691817
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hypovitaminosis D is a predictor of aromatase inhibitor musculoskeletal symptoms.
    Singer O; Cigler T; Moore AB; Levine AB; Do HT; Mandl LA
    Breast J; 2014; 20(2):174-9. PubMed ID: 24467395
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vitamin D deficiency and bone mineral density in postmenopausal women receiving aromatase inhibitors for early breast cancer.
    Nogues X; Servitja S; Peña MJ; Prieto-Alhambra D; Nadal R; Mellibovsky L; Albanell J; Diez-Perez A; Tusquets I
    Maturitas; 2010 Jul; 66(3):291-7. PubMed ID: 20399042
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systemic therapies for preventing or treating aromatase inhibitor-induced musculoskeletal symptoms in early breast cancer.
    Roberts KE; Adsett IT; Rickett K; Conroy SM; Chatfield MD; Woodward NE
    Cochrane Database Syst Rev; 2022 Jan; 1(1):CD013167. PubMed ID: 35005781
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of YOCAS©® yoga for musculoskeletal symptoms among breast cancer survivors on hormonal therapy.
    Peppone LJ; Janelsins MC; Kamen C; Mohile SG; Sprod LK; Gewandter JS; Kirshner JJ; Gaur R; Ruzich J; Esparaz BT; Mustian KM
    Breast Cancer Res Treat; 2015 Apr; 150(3):597-604. PubMed ID: 25814054
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Women commencing anastrozole, letrozole or tamoxifen for early breast cancer: the impact of comorbidity and demographics on initial choice.
    Kemp A; Preen DB; Saunders C; Boyle F; Bulsara M; Holman CD; Malacova E; Roughead EE
    PLoS One; 2014; 9(1):e84835. PubMed ID: 24392158
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aromatase inhibitors and musculoskeletal pain in patients with breast cancer.
    Winters L; Habin K; Gallagher J
    Clin J Oncol Nurs; 2007 Jun; 11(3):433-9. PubMed ID: 17623627
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized trial of vitamin D3 to prevent worsening of musculoskeletal symptoms in women with breast cancer receiving adjuvant letrozole. The VITAL trial.
    Khan QJ; Kimler BF; Reddy PS; Sharma P; Klemp JR; Nydegger JL; Yeh HW; Fabian CJ
    Breast Cancer Res Treat; 2017 Nov; 166(2):491-500. PubMed ID: 28770449
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Single arm phase II study of oral vitamin B12 for the treatment of musculoskeletal symptoms associated with aromatase inhibitors in women with early stage breast cancer.
    Campbell A; Heydarian R; Ochoa C; Dwivedi AK; Nahleh ZA
    Breast J; 2018 May; 24(3):260-268. PubMed ID: 29442401
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High prevalence of low vitamin D and musculoskeletal complaints in women with breast cancer.
    Napoli N; Vattikuti S; Ma C; Rastelli A; Rayani A; Donepudi R; Asadfard M; Yarramaneni J; Ellis M; Armamento-Villareal R
    Breast J; 2010; 16(6):609-16. PubMed ID: 21070438
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acute effects of tamoxifen and third-generation aromatase inhibitors on menopausal symptoms of breast cancer patients.
    Morales L; Neven P; Timmerman D; Christiaens MR; Vergote I; Van Limbergen E; Carbonez A; Van Huffel S; Ameye L; Paridaens R
    Anticancer Drugs; 2004 Sep; 15(8):753-60. PubMed ID: 15494636
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Debilitating musculoskeletal pain and stiffness with letrozole and exemestane: associated tenosynovial changes on magnetic resonance imaging.
    Morales L; Pans S; Paridaens R; Westhovens R; Timmerman D; Verhaeghe J; Wildiers H; Leunen K; Amant F; Berteloot P; Smeets A; Van Limbergen E; Weltens C; Van den Bogaert W; De Smet L; Vergote I; Christiaens MR; Neven P
    Breast Cancer Res Treat; 2007 Jul; 104(1):87-91. PubMed ID: 17061044
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum 25-hydroxyvitamin D and cancer-related fatigue: associations and effects on depression, anxiety, functional capacity and health-related quality of Life in breast cancer survivors during adjuvant endocrine therapy.
    Custódio IDD; Nunes FSM; Lima MTM; de Carvalho KP; Alves DS; Chiaretto JF; Canto PPL; Paiva CE; de Paiva Maia YC
    BMC Cancer; 2022 Aug; 22(1):860. PubMed ID: 35933326
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aromatase inhibitor-induced loss of grip strength is body mass index dependent: hypothesis-generating findings for its pathogenesis.
    Lintermans A; Van Calster B; Van Hoydonck M; Pans S; Verhaeghe J; Westhovens R; Henry NL; Wildiers H; Paridaens R; Dieudonné AS; Leunen K; Morales L; Verschueren K; Timmerman D; De Smet L; Vergote I; Christiaens MR; Neven P
    Ann Oncol; 2011 Aug; 22(8):1763-9. PubMed ID: 21273342
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.